Clarke, Paul A. http://orcid.org/0000-0001-9342-1290
Roe, Toby
Swabey, Kate
Hobbs, Steve M.
McAndrew, Craig
Tomlin, Kathy
Westwood, Isaac
Burke, Rosemary
van Montfort, Robert
Workman, Paul
Funding for this research was provided by:
Cancer Research UK (C309/A11566, C309/A11566, C309/A11566, C309/A11566, C309/A11566, C309/A11566, C309/A11566, C309/A11566, C309/A11566, C368/A6743, A368/A7990)
Kidani Memorial Fund
Article History
Received: 4 September 2018
Revised: 3 January 2019
Accepted: 22 February 2019
First Online: 25 March 2019
Compliance with ethical standards
:
: The authors are employees of The Institute of Cancer Research, which has a commercial interest in the discovery and development of PI3K inhibitors, including pictilisib, and operates a rewards-to-inventors scheme. PW and PAC have been involved in a commercial collaboration with Yamanouchi (now Astellas Pharma) and with Piramed Pharma and intellectual property arising from the program was licensed to Genentech. PAC is also involved in commercial collaborations with Merck KGaA and Astex Pharmaceuticals. PW was previously a scientific founder, consultant, Scientific Advisory Board member and stock holder of Piramed Pharma (acquired by Roche). He was a scientific founder, consultant, Scientific Advisory Board member, Board member and is a stockholder of Chroma Therapeutics. PW is also a consultant/advisor to Astex, CV6 Therapeutics and NextechInvest, and is a Non-Executive Director and stockholder of STORM Therapeutics. ICR receives research funding and income from numerous commercial partners.